-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90

Benzinga·11/04/2026 21:11:40
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.